Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MW05 vs Jinyouli for prevention of chemotherapy-induced neutropenia in breast cancer
CTR20201813Phase 3Completed
- Sponsor
- Taikang Biopharmaceutical
- Start
- Sep 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of rHSA-GCSF in chemotherapy-induced neutropenia (CIN), breast cancer, sponsored by Taikang Biopharmaceutical. Started Sep 2020; status: completed.
02
Drugs
rHSA-GCSF
03
Conditions
chemotherapy-induced neutropenia (CIN)breast cancer
Beyond the preview
Go deeper on CTR20201813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201813.